MetaCap

Immatics N.V. (IMTX)

NASDAQ: IMTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

5.77-0.18 (-3.03%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IMTX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$878.58M
EPS (TTM)
-$1.95
52-week range
5.72 – 12.41
Day range
5.72 – 5.95
Volume / Avg
746.64K / 962.74K
Beta
—

52-week range

$5.72$12.41

IMTX stock today

On Nov 20, IMTX ended the session at $5.77, shedding $0.18 (3.03%), versus the S&P 500's 3.70% decline. At this level, IMTX sits near the bottom of its 52-week range of $5.72 to $12.41: 53.5% below the high, set on Dec 4, 2025 and 1.0% above the low. IMTX is down 45.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 43.4%.

Immatics N.V. has posted a net loss over the last twelve months (EPS of -$1.95), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Immatics N.V.

Company profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Harpreet Singh Ph.D.
Headquarters
Tübingen
Employees
721

Analyst forecast

Forecast

Consensus (9 analysts)

strong_buy

Avg. price target

$15.97+176.78%

  • Strong buy 0
  • Buy 9
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $11.80High $21.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.58 vs $-0.49
Surprise
-18.37%

IMTX news

All IMTX news

Immatics N.V. peers

Health Care sector
IMTX peer companies
CompanyPrice% ChgMarket capCompare
ODTXOdyssey Therapeutics Inc.16.96-7.52%$815.23Mvs IMTX
BBTXBambusa Therapeutics Inc.16.00+2.89%$815.08Mvs IMTX
PRMEPrime Medicine Inc.3.55-7.55%$791.62Mvs IMTX
MGTXMeiraGTx Holdings plc7.98-1.97%$779.89Mvs IMTX
INBXInhibrx Biosciences Inc.68.97-7.21%$1.02Bvs IMTX
GLUEMonte Rosa Therapeutics Inc.8.64-3.03%$738.29Mvs IMTX
AURAAura Biosciences Inc.6.87-1.58%$714.99Mvs IMTX
SLDBSolid Biosciences Inc.6.25-2.95%$697.57Mvs IMTX

Indexes, lists and sector

Immatics N.V. stock FAQ

What is Immatics N.V.'s stock price today?

IMTX last traded at $5.77 as of Nov 20, 4:00 PM EST, down 3.03% on the day. Prices are delayed at least 15 minutes.

Who is Immatics N.V.'s CEO?

Dr. Harpreet Singh Ph.D. is the chief executive officer of Immatics N.V., which has about 721 employees.

What is the IMTX 52-week high?

The 52-week high for IMTX is $12.41 and the 52-week low is $5.72. The stock is currently 53.5% below its high.

Compare IMTX